Research Participant Registry Join Now!
 
Immune System/Infections


If you are interested in hearing more about one or more of the studies listed below, and you are already a Registry participant, please contact the Research Participant Registry at 1-866-438-8230 or via e-mail researchregistry@hs.pitt.edu.

Pulmonary Study University of Pittsburgh PRO10060177
Men and women between the ages of 30 and 70 years old needed for lung function study. Participants will complete a questionnaire, participate in pulmonary function testing, provide a blood specimen, provide a sputum specimen, and have fat tissue biopsied (optional). Must be current or former smokers. Compensation provided.

EpiPrEP Pitt Pilot Study University of Pittsburgh PRO15010326
Are you a HIV-negative man who has sex with other men? Are you planning on going away on vacation soon? If so, you may be eligible to participate in a study to help investigators test the feasibility and acceptability of short-term PrEP. PrEP is taking medications typically used to treat HIV to help prevent HIV. Compensation provided.

ACTG A5324 University of Pittsburgh PRO15010378
Are you HIV-infected and are you having problems with your memory or daily activities? If so, you may be eligible to help researchers see if adding study drugs maraviroc (MVC) and/or dolutegravir (DTG) to your current medication regimen will improve your ability to concentrate, remember, solve problems and make decisions. Study participation will last about 96 weeks. Compensation provided.

ACTG A5342 University of Pittsburgh PRO15040387
Are you between the ages of 18 and 65 and HIV-infected? Have you been on continuous ART for 2 years, and do you have a CD4 count over 200? If so, you may be eligible to help researchers see if an experimental monoclonal antibody called VRC01 is safe and well-tolerated in HIV positive people and to see if VRC01 helps reduce the number of HIV infected cells in the body. Compensation provided.

ACTG A5346: Trial for Sitagliptin for Reducing Inflammation and Immune Activation University of Pittsburgh PRO15070233
HIV-infected adults needed for a study to help researchers evaluate whether a FDA-approved drug (sitagliptin) that is used to treat type 2 diabetes can reduce inflammation and immune activation markers in HIV-infected men and women who are taking antiretroviral medication when compared to placebo (dummy pill). Study participation will last up to 8 months. Travel costs reimbursed.

ENT Research – Healthy Volunteers University of Pittsburgh PRO13040386B
Are you a healthy adult between 18 and 50 years old? Had previous middle-ear disease with or without ear tubes, even as a child? If so, you may be eligible for a study to determine if having nasal allergies increases the rate of blood-flow in the lining of the middle ear. Must have no chronic illnesses or known allergies. Study involves 2 visits to Children’s Hospital. Compensation provided.

REPRIEVE Heart Study University of Pittsburgh PRO15010395
Participants are invited to join a study about heart disease prevention in people with HIV. Eligible participants are between 40-75 years old, have been on retroviral therapy (ART) for at least 6 months, have a CD4+ cell count>100, have no history of cardiovascular disease, and are not currently using a statin drug. Study participation will last approximately 72 months. Compensation provided.

ENT Research – Healthy Volunteers PRO13040386B
Are you a healthy adult between the ages of 18 and 50? If so, you may be eligible to participate in a study to determine if allergic rhinitis (nasal allergy) increases the rate of blood-flow in the lining of the middle ear. Participants must have no chronic conditions or any known allergies. This study requires two visits to Children’s Hospital of Pittsburgh. Compensation provided.

Rituximab in Myasthenia Gravis University of Pittsburgh EXT14010027
The purpose of this study is to learn if rituximab is a safe and effective drug for people with Myasthenia Gravis (MG) who are on prednisone. It will also help determine if rituximab can help people take less, or possibly discontinue, prednisone. Eligible participants are 21 to 90 years old, have a diagnosis of generalized MG and must be taking a stable dose of prednisone. Compensation provided.

Pemphigus Vulgaris Study Quorum Review, Inc. 28302/3
Do you have pemphigus vulgaris? If so, you may be eligible to participate in a study to test an investigational drug to see if it will work to help with pemphigus vulgaris symptoms. Participation requires 18 study visits. The study will last over 1 year. Participants will be compensated.

ACTG A5320 PRO14010146
Have you been in a Hepatitis C treatment research study within the past year? If so, you may be eligible to participate in a study where your experience can help researchers develop better ways to treat Hepatitis C. Study visits are twice a year, plus a visit before starting any new Hepatitis C treatment. No medications are provided by this study. Parking/travel-related expenses reimbursed.

ACTG A5314 PRO13090071
Are you at least 40 years of age? Are you HIV-1 positive? People who have an undetectable HIV viral load while on HIV medications for the past 6 months, have a CD4 cell count of at least 400, and have active heart disease or are at risk for heart disease may be eligible to participate in this study that will look at the effects of a medication on inflammation and heart health in those with HIV.

ENT Research – Ragweed Study PRO13040368A
Do you have ragweed allergy? Are you a relatively healthy adult between the ages of 18 and 50? If so, you may be eligible to participate in a study to determine if allergic rhinitis (nasal allergy) increases the rate of blood-flow in the lining of the middle ear. This study requires three visits to Children’s Hospital of Pittsburgh. Compensation provided.

CHIC II Study PRO11120183
Are you a generally healthy woman between the ages of 18 and 34 years old who has regular periods? If so, and if you are not pregnant or currently using hormones for birth control, you may be eligible to participate in a study to better understand how birth control affects the immune cells within the reproductive tract. Compensation is provided.

HIV Prevention Research Registry PRO11110371
Are you interested in learning about HIV prevention research studies taking place at the University of Pittsburgh and UPMC? If so, you can join the HIV Prevention Research Registry. HIV prevention registry members may be contacted by registry staff members about studies for which they appear to qualify. Eligible participants are ages 18 and older.

To find out about the Research Participant Registry and opportunities to participate in research studies (or to withdraw from the Registry),
contact researchregistry@hs.pitt.edu or call 1-866-438-8230.
This website is maintained by the Clinical and Translational Science Institute.
If you have any technical difficulty please submit your help request here.
© Office of the Senior Vice Chancellor for the Health Sciences, University of Pittsburgh. All rights reserved.